u/b12_baseline

satiety signalling rather than incretin signalling

"the baseline panel i almost did not bother getting" is the most common sentence of regret and relief on this whole site.

get baseline labs before you start. i will keep saying it in every thread until it stops being necessary, which will be never.

Reading a trace posted here, in the order I actually look at things.

Axes first — if the wavelength and the time axis are not labelled, I stop. Then the baseline: where has it been drawn, and does the drawing absorb anything. Then peak shape: fronting, tailing, a shoulder that never resolves. Then the blank, if one was run, for carryover.

Only after all of that do I look at the percentage, and by then I usually know how much weight it deserves. The number is the last thing on the page and the first thing everybody argues about, which is exactly backwards.

Research-use-only material is not approved for human use. Anything in this thread about how a research vial "should" titrate is a discussion about chemistry, not a plan.

Weight change and appetite change are different endpoints on different timescales. Conflating them is where most of the confusion on this board starts.

The step schedule question, answered properly, because it comes up weekly.

The label sets a minimum interval of four weeks between increases. That is a floor on how fast you may go, and it exists because tolerability, not efficacy, is what limits most people. There is nothing in the pharmacology that says you must increase at four weeks, or at eight, or ever.

What decides it in practice is whether the effect you want is still there. If appetite is quiet and the trend is going the right way, the dose is doing its job. If both have genuinely gone flat for six weeks or more, that is a conversation worth having with someone who knows your history.

waist monthly, weight weekly, notes whenever

the trials titrated on a calendar, real people titrate on symptoms

SURMOUNT-1 ran 72 weeks with the top arm around 21% mean body weight change. SURPASS is the diabetes programme and reports glycaemic endpoints, so quoting the two interchangeably is a category error.

Small fix — 214nm, not 210. It matters for the comparison you are making with the other run.

Correction to my own post above — I said 15mg and I have been on 2.5mg since the spring. Same argument, wrong number.

the monotherapy numbers are modest and that is not the point

It is a dual GIP and GLP-1 receptor agonist, and the GIP arm is the part that has no equivalent in the semaglutide threads. That is why the side-effect profile reads differently rather than just milder.

Started reporting my own integrations with the baseline choice stated. Arguments in my threads dropped by about half.

reproducibility beats resolution if you only get one of them

Is there any independent purity data on this compound that you have seen?

Do you have the mass, or only the UV trace?

switching from sema is not a dose conversion, there is no clean equivalence

you cannot report to two decimals off that baseline

Disagree. 2.4 is the top of the label, not the goal, and "everyone ends up there" is just survivorship in the posts you read.

That template is elaborate enough that you will stop using it by week ten. Mine was.

protein first, then everything else gets easier

Adding one thing to this: the appetite effect and the scale run on separate clocks, so both halves can be true at once.

Correct, and worth adding: the trial average is an average. Half the people in it did worse than 15% and were still on the drug.

sulphur burps are the signature complaint and they are not dangerous

Yes. Week 62 is when almost everybody writes the "is it still working" post, and almost everybody is fine.

Delayed gastric emptying is most pronounced early and attenuates with continued dosing, which is why the reflux usually fades at a stable dose.

dual agonist, so the GIP arm is doing something the sema threads will not tell you about

week 2 is early to draw any conclusion at all

Gave the same trace to two people I trust and got two integrations about a point apart. That was the most educational afternoon I have had here.

Contemporaneous records do not drift; reconstructed ones do, and the drift is systematic rather than random because memory smooths.

stepping every four weeks is a ceiling on speed, not a schedule you must hit

Not convinced.

Adding one thing to this: the appetite effect and the scale run on separate clocks, so both halves can be true at once.

Delayed gastric emptying is most pronounced early and attenuates with continued dosing, which is why the reflux usually fades at a stable dose.

Right, and the timescale is the bit that keeps getting lost. Judge a step at a month, not at a weekend.

if 7.5 is working, 10 is not automatically better

Right, and the tolerability data in the combination arms is the part worth reading properly rather than summarising.

Why two honest labs report different numbers on the same vial.

Start with the gradient. A shallower slope holds compounds on the column longer and usually separates close-eluting species better. A steeper one gets you a faster run and a fatter peak. If a related substance elutes near the main peak, one method resolves it and reports it separately, the other absorbs part of it into the main peak.

Then integration. Where the baseline is drawn under a shoulder is a decision made by a person or by a piece of software configured by a person. It moves the number.

A point or two of spread between services on this assay is ordinary. Treating one lab as ground truth is how people end up in arguments with suppliers that neither side can win.

Is that baseline drawn by the software or by hand?

log what you did, not what you meant to do